Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments
- NURTEC® ODT (rimegepant) net product revenues for the fourth quarter of 2020 were $35.1 million, representing a 98% increase compared to the third quarter of 2020, and $63.6 million for calendar year 2020 following U.S. commercial launch in March of 2020
- Exceeded market expectations with robust growth of NURTEC ODT totaling over 337,000 prescriptions in 2020 and over 24,000 unique prescribers
- Regulatory filing for rimegepant in Europe submitted and accepted for review by European Medicines Agency for dual-acting (acute and prevention) indication for treatment of migraine
- Life-cycle management studies for CGRP-antagonist program underway, including initiation of Phase 4 study of NURTEC ODT in pediatric migraine
Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Biohaven Provides Update On ESG Practices
News provided by
Share this article
Share this article
NEW HAVEN, Conn., Feb. 8, 2021 /PRNewswire/ Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the Company or Biohaven ), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates today announced the advancement of several important steps that underscore the company s commitment to sound Environmental, Social and Governance ( ESG ) practices.
Maximizing long-term shareholder value and managing resources responsibly remains a key driving force for Biohaven s ESG strategy, with the Company dedicated to bringing innovative medicines forward for patients and to grow value for investors while maintaining an efficient and high-performing culture.